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 A Drug designing is a process in which new leads (potential drugs) are 
discovered which have therapeutic benefits in diseased condition. With 
development of various computational tools and availability of databases 
(having information about 3D structure of various molecules) discovery of 
drugs became comparatively, a faster process. The two major drug 
development methods are structure based drug designing and ligand based drug 
designing. Structure based methods try to make predictions based on three 
dimensional structure of the target molecules. The major approach of structure 
based drug designing is Molecular docking, a method based on several 
sampling algorithms and scoring functions. Docking can be performed in 
several ways depending upon whether ligand and receptors are rigid or flexible. 
Hotspot grafting, is another method of drug designing. It is preferred when the 
structure of a native binding protein and target protein complex is available and 
the hotspots on the interface are known. In absence of information of three 
Dimensional structure of target molecule, Ligand based methods are used. Two 
common methods used in ligand based drug designing are Pharmacophore 
modelling and QSAR. Pharmacophore modelling explains only essential 
features of an active ligand whereas QSAR model determines effect of certain 
property on activity of ligand. Fragment based drug designing is a de novo 
approach of building new lead compounds using fragments within the active 
site of the protein. All the candidate leads obtained by various drug designing 
method need to satisfy ADMET properties for its development as a drug. In-
silico ADMET prediction tools have made ADMET profiling an easier and 
faster process. In this review, various softwares available for drug designing 
and ADMET property predictions have also been listed.  
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1. INTRODUCTION  
 
A drug is a small organic molecule which has therapeutic benefits as it activates and 
inhibits function of a biomolecule which can be an enzyme , receptors (circulating 
messengers), targets involved in cell replication and protein synthesis (DNA , RNA) and 
Transport systems (ion channels).A drug molecule can be developed by a process known as 
Drug Designing, in which the knowledge of the biological target is used .Traditionally Drug 
development was based on random trial and error methods which was highly time consuming 
and a very expensive method and had extremely low yield (1 in 100,000) [1][2][3]. This 
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process has now been facilitated by the development of computational tools and 
methodologies. This Computer Based Drug Designing is target specific and structure based, 
comparatively fast and has low cost and high success rate. There are two major types of drug 
designing approaches, structure based drug design and ligand based drug design. 
 
STRUCTURE BASED DRUG DESIGNING: 
 
Structure based drug design [4] is based on three dimensional structural information 
which is obtained by modern biophysical techniques like NMR and X-ray crystallography. If 
the three dimensional structure is not known then homology modelling is performed to 
predict the structure of the target, based on the structure of the related proteins. General 
methodology of structure based drug designing [5] (Figure 1) begins from 3D structure of 
target (available in structural databases or generated through homology modelling) which is 
then docked against compounds (Ligands) in the databases. The ligated structures with best 
scores are then determined, refined and analysed to find sites on ligand involved in binding to 
target. These sites can further be optimised to increase the potency of ligand. This is followed 
by cell based or biochemical assay and clinical trials. Structure based drug designing is an 
iterative process, if potency of ligand is poor then next ligand in the list is tested through all 
the steps discussed above. While choosing a drug target- function prediction, pathway 
information, disease association and structural data must be considered. Similarly ligand 
selection must also be accurate, so that it specifically binds to the target and produce a well-
defined physiological effect, simultaneously minimising undesired side effects. Ligands used 
in drug designing must follow Lipinski Rules to be a successful drug candidate. 
 
Lipinski Rules: 
1. five or fewer hydrogen-bond donors 
2. ten or fewer hydrogen-bond acceptors 
3. molecular weight less than or equal to 500 
4. calculated logP less than or equal to 5 
 
 
The most common method which is widely used in structure based drug designing is 
Molecular docking [6]. Molecular Docking is a method to characterize the behaviour of small 
molecules and binding site of the target protein, by modelling the interaction between a small 
molecule and protein. Two basic steps involved in docking method are: Use of sampling 
method to predict ligand conformation as well as the pose (position and orientation) of small 
molecule (ligand) within the binding sites and scoring schemes for assessment of binding 
affinity [6].  
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Figure 1.  General methodology of structure based drug designing 
 
In most of the cases position of binding site in target molecule is known, which 
increases the docking efficiency. However in absence of such prior information binding site 
prediction program or online servers such as GRID [7][8], POCKET [9], SurfNet [10][11], 
PASS [12] and MMC [13] can be used. Various sampling algorithms used in Molecular 
Docking are [6]: 
 
Matching algorithms (MA): 
Matching algorithms [14][15][16] mainly takes into account overlap between two molecules 
to identify possible binding sites of a protein by molecular surface search [17]. In this 
algorithm, docking is guided by generating pharmacophores that represents protein and 
(initial conformation of) ligand. These ligand and protein pharmacophores are then studied 
for a match by comparing distances between each of the pharmacophoric points on them. In 
3D structure of target molecule is known otherwise homology modelling 
can be used to generate 3D structure of target molecule based on structure 
of closely related protein. 
 
Detect active sites 
 
Dock the targets against the compounds in the database. 
 
Ligated structures on top of the list are 
determined and refined.  
    
    
  
 
Each of the ligated structure is analysed to find sites in the ligand 
involved in binding to targets. 
 
These sites on ligand can be optimised to increase the potency 
(involves redesigning of ligand).  
Ligands that have been designed are then synthesized and tested 
through cell based or biochemical assay. 
       Clinical Trials 
Commercial Drug 
Iterative 
process 
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case of a match, the ligand and proteins are placed in same reference frame, by calculation 
and implementation of translational and rotational vectors on ligands [18].  Several software's 
using this algorithm are: DOCK [19][20][21][22], FLOG [23], LibDock [24] and SANDOCK 
[25]. 
 
Fragment based method: 
 Incremental construction 
 Incremental construction algorithm uses greedy strategy along with overlap detection 
method to find new interactions. [26].  This algorithm divides ligand into fragments through 
rotable bonds which are then docked separately in receptor sites in an incremental fashion 
and are later on fused together [17]. Usually in this method, base fragment chosen is the 
largest fragment having some significant role in interaction with proteins [27]. Several 
software‟s using this algorithm are: DOCK 4.0 [28], FlexX [29] [30], FLOG [31], Surflex 
[32] [33], Hammerhead [34], SLIDE [35] and eHiTS [36]. 
 
 Multiple Copy Simultaneous Search (MCSS)  
In MCSS approach, [37][38] energetically favourable positions and orientations of different 
functional groups in binding sites are identified by first generating 1000 to 5000 copies of 
functional group which are then placed randomly in the binding site and are subjected to 
energy minimization or molecular dynamics. This process yields functionality maps of the 
binding sites [6] [39]. New ligands complementary to binding sites are then constructed by 
linking functional groups positioned in these energetically favourable positions.  
 
 LUDI 
The LUDI algorithm is a molecular-fragment based approach and takes into account 
hydrogen bond and hydrophobic interactions between ligand and protein. It is used for 
identification of the potential de novo leads [6].  Ludi follows three steps: identification of 
interaction sites between protein and ligand, identification of fragments (from fragment 
library) which form hydrogen bonds and fill hydrophobic pockets on the target and finally 
connection of these fragments with linkers to make a single molecule. The capability of Ludi 
for designing new ligands was demonstrated by development of HIV protease and DHFR 
inhibitors [40] [41] [42] [43]. 
 
Stochastic methods: 
 Monte Carlo (MC)  
This method [44] [45] is used to produce different poses of the ligand (from initial 
configurations) inside a receptor binding site (through bond rotation, rigid body translation or 
rotation). Each conformation generated is applied to a force field based energy minimization 
[6]. Minimized conformation obtained is considered as parent conformation (if it satisfies the 
selection criteria) and is further modified to generate next conformation. This process is 
repeatedly performed till specified number of conformations are generated. Main advantage 
of this method is that ligand may cross the energy barriers on the potential energy surface 
owing to large and random changes. Several software's using this algorithm are:  AutoDock 
[46], ICM [47], QXP [48] and Affinity [Accelrys Inc., San Diego, CA, USA.][6]. 
 
 Genetic algorithms 
Genetic algorithm [49] [50] [51] is based on Darwinian evoloution theory. It is an EP 
algorithm and does function optimization [52] [53] [54]. It has two types of genetic operators: 
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crossover and mutations. Mutation refers to random changes to the genes, and crossover 
refers to exchange of genes between two chromosomes [6]. Either of these two results in a 
new ligand structure with best characteristics from each of parent. Genotypic Mutations 
which work as local search operator in traditional genetic algorithm have different role in 
Lamarckian genetic algorithm (LGA). The LGA uses explicit local search operator and swaps 
between genotypic and phenotypic space .Several software‟s using this algorithm are: 
AutoDock [49], GOLD [55], DIVALI [56] and DARWIN [57]. [6]. 
 
Molecular dynamics (MD): 
It is a powerful simulation method widely used in many fields of molecular modelling. 
MD Simulation considers motion of individual particle as a function of time providing 
physical basis of the structure and thus helps in understanding biomolecular function. Since 
Molecular dynamics progress in very small steps thus difficulties in stepping over high 
energy conformational barriers are faced, leading to inadequate sampling [6]. In MD 
Simulations selection or removal of several factors can be done in order to determine their 
effect on the system. Molecular dynamics simulations along with simulated annealing can be 
used to sample configuration space by refining structures from experimental data, which 
further helps to understand structural thermodynamics and motional properties of system at 
equilibrium [58].  Programs based on Molecular dynamics are: CHARMM [59], AMBER 
[60] and GROMOS [61].  
 
Table 1: Algorithms and their respective softwares 
 
ALGORITHM   SOFTWARE  
Matching algorithms (MA)   DOCK , FLOG , LibDock  , SANDOCK 
Incremental construction DOCK 4.0 , FlexX , Hammerhead , SLIDE , eHiTS  
Monte Carlo (MC)  AutoDock , ICM , QXP  , Affinity 
Genetic Algorithms AutoDock , GOLD , DIVALI  , DARWIN 
 
SCORING FUNCTIONS: 
Accuracy of docking hits depends on quality of scoring function, which is based on 
estimation of binding affinity between protein and ligand. It is of three main types [6]: 
Force field based: [62] [63] [64] It measures the binding energy by calculating the 
summation of the non-bonded (electrostatics and van der Waals) interactions. A drawback of 
this scoring method is the problem of slow computational speed. DOCK [19] [20] [21] [22], 
GOLD [55], FlexiDock, Tripos, CHARMM [59], AMBER [60] and AutoDock [46] are 
Force field based Software‟s. 
 
Empirical based:[65][66][67][68][69] In this scoring method each component of 
decomposed binding energy, such as hydrogen bonds, ionic interaction, hydrophobic effect 
and binding entropy, is multiplied to a coefficient before being summed up to a final score . 
LUDI, AutoDock, PLP [66] [67] [70] and ChemScore [71] are examples of Empirical based 
scoring method. 
 
Knowledge based: [72] [73] [74] [75] [76] [77] In this method, interatomic contact 
frequencies between ligand and protein are calculated using statistical analysis of ligand 
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protein complexes crystal structures. Several unusual interactions like sulphur-aromatic or 
cation-pi can be modelled through this function. PMF, DrugScore [78], SMoG [79] and Bleep 
are several knowledge-based functions. 
 
Consensus scoring [80] is another scoring method which calculates score by combining 
several different scores. CScore is based on consensus scoring method, it combines DOCK 
[19] [20] [21] [22], ChemScore, PMF, GOLD, and FlexX scoring functions. Though this 
method might give inaccurate information at times. 
Docking can be performed in three ways: 
 
1. Rigid Receptor and Rigid Ligand Docking: In this case both ligand and receptor are 
treated as rigid body‟s i.e, flexibility is not considered in either case. This method 
considers only three translational and three rotational degrees of freedom and thus the 
search space is limited.[6] 
2. Rigid Receptor and Flexible Ligand Docking: In this case ligand flexibility is taken 
into consideration while receptor is treated as the rigid body.[6] 
3. Flexible Receptor and Flexible Ligand Docking: To study interactions between the 
receptor (protein) and the ligand in a better way it is important to consider flexibility in 
receptor as binding of ligand leads to a conformational changes in protein. There are four 
methods that account for protein flexibility in docking.[6] 
Soft Docking:  It works by decreasing the extent of overlap between the ligand and receptor 
by decreasing the van der Waals repulsion energy in docking calculations. It is the simplest 
method that implements receptor flexibility but considers only small conformational changes. 
[81][82][83]  
Side-Chain Flexibility: This method make use of roamer libraries which contain set of 
different conformations of the side chain. In this case backbone is fixed and only side chain 
flexibility is considered i.e. different side chain conformations are sampled. [81][84][85]  
Molecular Relaxation: This method takes in account both backbone as well as side chain 
flexibility. The ligand is first docked to the binding site of the rigid receptor and then the 
receptor-ligand complex is minimized (relaxed) by molecular dynamics, Monte Carlo 
simulations or through other methods. [81][86]  
Ensemble docking: This method makes use of an ensemble of different conformations of a 
protein structure. The ligand is then docked to each rigid protein conformation in the 
separately. Finally, the results are merged. [6][87]  
 
HOTSPOT GRAFTING 
 
Hotspot Grafting is a new method for designing protein drugs [88]. Residues on protein 
interfaces that dominate binding energy are known as hotspots [89].  If the structure of a 
native binding protein and target protein complex is available and the hotspots on the 
interface are known, then the hotspot grafting strategy is a good choice. 
 In this method, scaffold proteins that can accommodate hotspots are searched [88]. 
Sites accommodating hotspot patterns are detected using pharmacophoric pattern matching 
approach like graph theory based approach or set reduction algorithm scaffolds [90]. Hotspot 
patterns found are thereafter transferred on these scaffold proteins. Then these are docked to 
target protein on the basis of hotspot superposition, out of these superposed complexes one‟s 
with higher scores are finally selected. Using Hot spot grafting strategy protein drugs may be 
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designed, for example; using above algorithm, rat PLCδ1-PH (plesksprin homology domain 
of phospholipase C-δ1) a scaffold protein, was searched by scanning PDB. This scaffold 
protein was made to bind to human erythropoietin receptor (EPOR) by grafting key residues 
involved in interaction with human erythropoietin receptor (EPOR).  Rat PLCδ1-PH 
(plesksprin homology domain of phospholipase C-δ1) is showed significant biology activity 
in cell-based assay and a good binding affinity with EPOR in-vitro. 
 
LIGAND BASED DRUG DESIGNING: 
 
 The ligand based method such as pharmacophore modelling and quantitative structure 
activity relationship (QSAR) methods are used when active ligand molecule are known but 
there is  little or no structural information available for the target.  Pharmacophore modelling 
can be used to search essential features for biological activity of active ligands which can 
further be used to screen molecules and QSAR is used to build models for prediction of   
activity of novel molecules [91]. Natural products or substrate analogues can also be used in 
ligand based drug designing which give desired pharmacological effect on interaction with 
target molecule [92]. 
 
PHARMACOPHORE: 
Pharmacophore can be defined as a molecular framework that defines necessary 
features that an active ligand should possess for a drugs biological activity [93] [94]. 
 
Pharmacophore Modelling: 
 Pharmacophore modelling is a process where pharmacophores can be queried against 
structural databases to: 
 retrieve potential leads ( Lead Discovery )  
 design molecules having specific desired attributes (Lead Optimization)  
 Assessing similarity and diversity of molecules using pharmacophore fingerprints. 
A Pharmacophore model is generated by initially performing literature searches and database 
queries (from both in house and public database) to assemble active compound sets. While 
searching the active compounds from these multiple sources a consistent threshold to define 
compound activity should be applied and molecules exerting biological effects via same 
mechanism should be taken into consideration. In case chemical structure for the molecule is 
not available, then several software‟s are used to manually sketch its structure. In next step 
pharmacophore model is build using common features found among ligands. The ligand 
aligned, are superimposed with the help either of a conformer database of relevant ligand or 
of an on-the-fly conformation generator to find common features [95] [91]. A Pharmacophore 
elucidation algorithm is use to generate pharmacophore models after the alignment step is 
completed. More than one output models are generated and the selection of best one is 
assisted by scoring function contained within pharmacophore building software. Generally, 
the model with highest score is selected and is subjected to validation process. 
 
QSAR 
QSAR, stands for “quantitative structure-activity relationships” and relates chemical structure 
to biological or chemical activity using mathematical models. A model can be generated to 
describe this relationship, if the activity of a set of ligands. Pharmacophore model explain 
only the essential feature of an active ligand whereas QSAR model determine the effect of 
certain property on the activity of ligand [96]. This set of property is computed from the 
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structure and use to quantify it. By using both structure descriptor and activity as an 
independence variable, a model can be built to describe the relationship between the two. The 
biological activity of novel molecules from their structural property can be predicted, after a 
QSAR model is build and validated [97]. The general methodology consists of following 
steps [92]: 
1. Ligands whose desired biological activity has been experimentally measured are 
identified. Ideally these ligands are of a congeneric series but should have an adequate 
chemical diversity to produce a large variation in activity. 
2. Molecular descriptor associated with various structural and physio-chemical property of 
molecule understudy are identified and determined. 
3. Correlation between molecular descriptors and the biological activity is discovered to 
explain the variation in activity in the dataset. 
4. Statistical stability and predicted power of QSAR model is tested. 
 
2D QSAR: 
In 2D QSAR various electronic, hydrophobic and steric properties are correlated with the 
biological activity [98] [99]. Descriptors used in 2D QSAR are independent from 3D 
orientation of the compound. Basic methods used to generate 2D QSAR models [92]: 
 
Multivariable Linear Regression Analysis (MLR): 
 Simplest method to describe correlation between molecular descriptor and activity. 
 Involves addition or removal of descriptor to generate best model. 
 Time consuming (especially when large numbers of descriptors are available). 
Principal Component Analysis (PCA): 
 Overcomes problem of MLR. 
 Extracts information from large number of variables to smaller number of 
independent variable. 
 Useful in case when large numbers of descriptors are available. 
 Outputs are difficult to analyze. 
Partial Least Square Analysis (PLS): 
 Combines MLR and PCA techniques. 
 Takes into consideration dependent variables also. 
 PLS are useful in systems that possess more than one dependent variable. 
3D QSAR 
3D QSAR methods are the methods, which include descriptors, describing 3D features (like 
various geometric, physical characteristics and quantum chemical) of a molecule, for 
development of QSAR model [92] [100]. 
Various major techniques of 3D QSAR modelling are: 
 
Comparative Molecular Field Analysis (CoMFA): 
The first QSAR method to find correlation between 3D shape dependent steric and 
electrostatic properties of a molecule to its biological activity was CoMFA [101]. CoMFA is 
based on an assumption that the minimum energy conformer is the bioactive conformer. In 
this method the aligned molecules (based on their 3D structure) are placed in a 3D grid and 
their steric and electrostatic potential energies are determined at each grid point [92] [100]. 
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Comparative Molecular Similarity Indices (CoMSIA): 
This method is similar to CoMFA but it considers hydrophobic, hydrogen bond donor and 
acceptor properties along with steric and columbic properties [102] [92]. It  also calculates 
the similarity indices by comparing each ligand molecule with a common probe with a radius 
of 1Å, and charge, hydrophobicity and hydrogen bond properties equal to 1 [100]. 
 
CATALYST  
CATALYST [Catalyst. Accelrys Inc.; SanDiego, CA: 2002.] is 3D QSAR software that 
considers conformational flexibility during model development [92]. To sample 
conformational space for the ligand it uses poling algorithm [103]. Several conformers are 
generated with a default cut-off value of 20 kcal/mol above the energy of global minimum 
conformation [92]. Pharmacophore hypothesis are then developed using spatial orientations 
of the functional groups. QSAR models are evaluated by comparing the estimated and 
observed activity values.  
 
Table 2: List of drug designing Softwares. 
Software’s Features 
AUTODOCK  Automated docking of flexible ligand 
COMBIBUILD Added design of combinational library 
DOCKVISION Include Monte Carlo, genetic algorithm, database screening 
docking algorithm 
FRED Multiconformation docking program 
FLEXIDOCK Conformational flexible ligand 
FLEXX Complex prediction, virtual screening, Boehm function applied 
for scoring 
GLIDE  High through put method, best binding method through monte 
Carlo sampling 
GOLD Calculate docking mode of small molecule into protein binding 
site, scoring function using like ChemScore, gold score. 
DOCK Design combinatorial library 
CLUSPRO Rigid docking base on the Fourier correlation approach(using 
DOT and ZDOCK docking program) 
HEX Use spherical Fourier correlation to accelerate docking 
calculation. 
FLEXX Predicting Protein –Ligand Interaction, Complex Prediction 
And Virtual Screening, Conformation Flexibility Of Protein 
HINT! Hydropathic Interaction, Calculate 3D Hydropathy Field And 
3D Hydropathic Interaction Maps, Estimates LogP For 
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FRAGMENT BASED DRUG DESIGNING 
 
Fragment based drug designing is an approach of  constructing  lead compounds ,using small 
,low molecular weight molecules known as fragments. This technique has certain/several 
advantages over high throughput screening [104]. 
 
Modelled Molecules 
LIGPLOT Automating Plotting Protein-Ligand Interactions, Interactions 
SITUS Program Package For Modelling Of Atomic Resolution 
Structure Into Low-Resolution Density Maps, Support Both 
Rigid-Body And Flexible Docking 
VEGA Calculation Of Ligand-Receptor Interaction Energy 
GRAMM Global Range Molecular Matching, Require Only The Atomic 
Coordinates Of The Two Molecules To Predict The Complex 
Structure, 
ICM-DOCK Fast And Accurate Docking Simulations,Uniques Set Of Tools 
For Accurate Individual Ligand –Protein Docking, Peptide-
Protein Docking 
BiGGER Biomolecular Complex Generation With Global Evaluation 
And Ranking, Efficient Protein-Docking Algorithm 
CLUSPRO Integrated Approach To Protein-Protein Docking, Docking 
Algorithm Include Refinement Of 25 Largest Cluster By 
Flexible Docking. 
DOT Daughter Of Turnip, Computation Of Electrostatic Potential 
Energy Between Two Proteins. 
ESCHER NG Enhance Version Of The Original ESCHER Protein-Protein 
Automatics Docking System Developed 
HADDOCK High Ambiguity Driven Protein-Protein Docking, Biochemical 
And Biochemical Interaction Data Such As Chemical Shift 
Perturbation Data Resulting From NMR. 
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 Low complexity of fragments, increases the probability of matching a target protein 
binding site, thereby screening only 100 to few 1000 compounds. 
 More hits with better binding efficiency are identified/obtained in comparison to HTS. 
 Lead compound obtained has low molecular weight as desired for lead likeliness. 
Fragment based strategy starts with selection of fragments which is mainly based on “Rule 
of three” [104,105] which includes: 
 
 Molecular weight < 300 
 cLogP  = 3 (Lipophilicity) 
 Number of Hydrogen bond donor and acceptor  < 3 
Along with these it has been found that fragments must have number of rotatable bonds, on 
average less than or equal to 3 and Polar surface area as 60A
2 
[104]. Fragment selection is 
followed by its screening. Several screening methods available are Nuclear magnetic 
resonance (NMR) , X- Ray Crystallography , Functional screening and Mass Spectrometry 
(both Tethering and Non-covalent). All these methods have their own advantages and 
disadvantages. In the last step fragments screened, are grown into potential drug leads. This 
can be done by four different methods [104] [105]. 
 
Fragment Evolution  
Direct binding techniques are used to identify initial fragment which is thereafter grown into 
larger molecule that target additional interactions in active site of protein.  This approach 
leads to more tighter binding molecules. 
 
Fragment Linking 
In this approach, fragments binding to separate sites that are close enough to be chemically 
linked are identified, thereby generating large molecule with high affinity. 
 
Fragment Self-Assembly 
This method is based on fragments to undergo self-assembly which is catalyzed by template 
(target protein). Fragments having complementary functional groups can thus be assembled 
to a larger and more potent molecule in presence of target protein. 
 
Fragment Optimization  
In this method lead molecules are re-engineered such that particular properties like 
selectivity, cell based activity, oral activity or efficacy can be optimized along with binding 
affinity. 
Though this is a powerful approach for drug lead generation, still fragment identification, 
their linking and merging is a difficult task. 
 
 
ADME 
Absorption, Distribution, Metabolism, Excretion and Toxicity are major causes that lead to 
failure of candidate leads in drug discovery process, thus these properties must be considered 
during development of a drug.  
 
Absorption: 
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The process by which a drug crosses the body membranes and enters the tissue or the blood 
plasma is called Absorption. Major factor [106] [107] [108] that influence absorption of drug 
are: 
a) Ionization constant (pKa) - It is a degree to produce ions in aqueous medium (For eg: 
water). Higher the value of pKa (strong acids/ strong bases), lesser is the absorption.  
 
b) Solubility - It is an important factor for determining oral bioavailability of the drug. Lower 
solubility leads to lesser absorption and thereby less bioavailability of drug.  
 
c) Lipophilicity - It describes tendency of the drug to prefer lipidic environment to that of 
aqueous. Higher value indicates high lipid solubility of drug. 
 
d) Drug particle size - Larger size of the drug prevents its diffusion across compartments 
leading to poor absorption. Therefore, the size of the drug must be optimum. 
 
e) Route of administration - Depending upon nature of drug , drug  can be administered via 
one of the several   routes  such as intravenous, oral, intramuscular, subcutaneous, inhalation , 
intraperetonial , etc.  
Distribution: 
Distribution of drug is important for it to reach the site of action. It is mainly affected by 
extent of absorption and factors affecting absorption, for example: ability of a drug to diffuse 
through membranes, and their solubility in lipid / water medium. Other factors that influence 
distribution are blood flow rate, tissue storage, metabolism and excretion of the compound 
and various physiological barriers. Binding of drug molecule to plasma protein  is another 
factor which causes decrease in their distribution rate as it reduces the amount of free drug in 
plasma [107][108]. 
 
Metabolism: 
Metabolism is a process of action of body on a drug molecule to convert it into an active 
agent, through various biochemical processes. Rate and extent of metabolism of a drug 
molecule depends on its chemical structure, physiochemical properties, enzymes involved 
and products formed.  Metabolism greatly affects drug dosage. Both Initial and maintenance 
Dose of a drug depends on whether a drug metabolizes rapidly or not. Frequent maintenance 
doses are required for rapidly metabolizable drugs (for maintaining its therapeutic index), 
which are not required for highly stable drugs [107] [108]. 
 
Excretion: 
Drugs are metabolized and excreted either in form of metabolites or as a parent drug. 
Excretion can be of either form such as breath, saliva, urine, faeces, milk, bile, perspiration 
and hair. Kidney plays the major role in elimination of drug from the body.  Factors affecting 
excretion are molecular weight of drug, its metabolites and its lipid solubility. Compounds 
having less lipid solubility (polar) are eliminated faster in comparison to those having high 
lipid solubility (non polar). Compounds having low molecular weight tend to eliminate 
through urine whereas those with high molecular weight are eliminated via bile [107] [108]. 
 
Toxicity: 
A drug is said to be toxic in either of three cases: 
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 When gets accumulated in the body in higher amounts.  
 Is not metabolized properly. 
 Causes severe side effects (such as when drug don‟t bind specifically to the target 
molecule). 
 
Toxicity is a major factor that causes failure of drug to reach market and for its withdrawal 
from market. It can be either acute or chronic depending upon period of time taken to cause 
toxic effect or damage to the body. Acute toxicity is when damage is caused by a single dose 
and in a short duration of time, whereas when body is repeatedly exposed to drug and toxic 
effects is caused after a prolonged period of time it is said to be chronic toxicity. Toxicity 
depends on various factors like patient's age, genetic composition, drug dosage and other 
medications taken by patient. 
 
Traditionally, drugs were synthesized first and then there pharmacokinetic properties, 
metabolism and toxicity were studied. With the use of combinatorial chemistry and high 
throughput screening a large no of new lead compounds are screened, many of these 
compounds fail because of inappropriate ADME properties. With advancement in 
technology, these studies are done much earlier before evaluating compounds in clinic 
through in-silico methods, saving both time and cost.  In ADME studies, pharmacokinetics 
parameters are evaluated (Table 3). A large no of these approaches have been developed to 
predict ADME properties [107] [108]. 
 
Table 3: List of some important pharmacokinetic parameters 
Terminology Definition 
Inhibitory 
Concentration (IC50) 
Concentration required to inhibit 50% of maximum response in 
a given test population. 
 
Lethal Dose (LD50) Concentration required to kill 50% of given test population 
Effective Dose (ED50) Concentration of drug producing an therapeutic response in 
50% of given test population 
Biological effect of Drug 
(E) 
Effect observed for a drug. 
Bound Drug(B) Amount of drug in bound form. 
Volume of Distribution 
(Vd) 
Amount of drug in body to the concentration of drug in blood or 
plasma. 
Rate of Elimination 
(Ke) 
The elimination rate constant can be defined as the fraction of 
drug in an animal that is eliminated per unit of time, e.g., 
fraction/h. Elimination half-life is the time required for the 
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amount of drug (or concentration) in the body to decrease by 
half. 
Clearance  (CL) Factor that predicts the rate of elimination in relation to the 
drug concentration. 
Half Life  (t1/2) Time required to change the amount of drug in the body by one 
half during elimination. 
Bioavailability  (F) 
 
Actual amount of drug available for action in plasma. 
Accumulation Amount of drug accumulated in body. 
Dosing Rate Amount of drug administered per unit time. 
Initial Dose Amount of drug initially administered. 
Maintenance Dose Amount of drug administered to maintain the therapeutic level 
of drug in plasma. 
 
CONCLUSION: 
 
Drug designing is a vast and ever-growing field, which involve knowledge of bioinformatics, 
proteomics, biochemistry and computer modelling. Structural interaction of a ligand with 
receptor or target molecule decides effectiveness of a drug. Structure based drug designing is 
one of the most widely used drug designing technique; in which docking is the most widely 
employed one. Beside this Pharmacophore modelling and QSAR are other important methods 
that are based on three dimensional structural information of ligands. Fragment based 
approach is a de-novo approach in which fragment libraries are explored for lead 
identification and has several advantages over high throughput screening. Inappropriate 
ADMET properties are the major cause of failure of a lead compound thus there is an 
increasing need for in-silico tools for ADMET prediction to reduce the rate of late stage 
attrition and further fasten the drug discovery process. Numerous algorithms, softwares and 
methods are emerging in this field, day by day.  All this advancement and up gradation of 
technology has made drug designing process much easier and faster. 
 
 
REFERENCES: 
    
   68              ISSN: 2278-8115 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
1. Geoffrey S. Ginsburg and Jeanette J. McCarthy. (2001) Personalized medicine: 
revolutionizing drug discovery and patient care. Trends in Biotechnology, 19: 491-
496. 
2. Soma Mandal, Meenal Moudgil, Sanat K. Mandal. (2009) Rational drug design. 
European Journal of Pharmacology, 625: 90–100. 
3. De-Xin Kong, Xue –Jan Li and Hang-Yu. (2009) Where is the hope for drug 
discovery? Let history tell the future. Drug Discovery Today, 14: 115-119. 
4. Tami J. Marrone, James M. Briggs and J. Andrew McCammon. (1997) Structure-
based drug design: Computational Advances. Annu. Rev. Pharmacol. Toxicol, 37:71–
90 
5. Amy C. Anderson. (2003) The Process of Structure-Based Drug Design. Chemistry &     
Biology, 10: 787–797. 
6. Xuan-Yu Meng, Hong-Xing Zhang, MihalyMezei and Meng Cui.(2011) Molecular 
Docking: A powerful approach for structure-based drug discovery. Curr Comput 
Aided Drug Des, 7(2): 146–157. 
7. Goodford PJ. (1985) A computational procedure for determining energetically 
favorable binding sites on biologically important macromolecules. J Med Chem., 
28(7):849–857. 
8. Kastenholz MA, Pastor M, Cruciani G, Haaksma EE and Fox T. (2000) GRID/CPCA: 
a new computational tool to design selective ligands. J Med Chem., 43(16):3033–
3044. 
9. Levitt DG, Banaszak LJ. (1992) POCKET: a computer graphics method for 
identifying and displaying protein cavities and their surrounding amino acids. J Mol 
Graph, 10(4):229–234. 
10. Laskowski RA. (1995) SURFNET: a program for visualizing molecular surfaces, 
cavities, and intermolecular interactions. J Mol Graph, 13(5):323–330. 
11. Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM. (2006) A 
method for localizing ligand binding pockets in protein structures. Proteins, 
62(2):479–488. 
12. Brady GP Jr. Stouten PF. (2000) Fast prediction and visualization of protein binding 
pockets with PASS. J Comput Aided Mol Des., 14(4):383–401. 
13. Mezei M. (2003) A new method for mapping macromolecular topography. J Mol 
Graph Model, 21(5):463–472. 
   69              ISSN: 2278-8115 
 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
 
14. Brint AT, Willett P. (1987) Algorithms for the Identification of Three-Dimensional 
Maximal Common Substructures. J. Chem. Inf. Comput. Sci., 27:152–158. 
15. Fischer D, Norel R, Wolfson H, Nussinov R. (1993) Surface motifs by a computer 
vision technique: searches, detection, and implications for protein-ligand recognition. 
Proteins,  16(3):278–292. 
16. Norel R, Fischer D, Wolfson HJ, Nussinov R. (1994) Molecular surface recognition 
by a computer vision-based technique. Protein Eng., 7(1):39–46. 
17. Raquel Dias1 and Walter Filgueira de Azevedo Jr. (2008) Molecular Docking 
Algorithms. Current Drug Targets, 9:1040-1047.  
18. N Moitessier, P Englebienne, D Lee, J Lawandi and CR Corbeil (2008) Towards the 
development of universal, fast and highly accurate docking/scoring methods: a long 
way to go. British Journal of Pharmacology, 153:S7–S26. 
19. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. (1982) A geometric 
approach to macromolecule-ligand interactions. J Mol Biol., 161(2):269–288. 
20. Kuntz ID, Leach AR. (1992) Conformational analysis of flexible ligands in 
macromolecular receptor sites. J. Comput. Chem., 13:730–748. 
21. Ewing TJ, Makino S, Skillman AG, Kuntz ID. (2001) DOCK 4.0: search strategies for 
automated molecular docking of flexible molecule databases. J Comput Aided Mol 
Des., 15(5):411–428. 
22. Shoichet BK, Stroud RM, Santi DV, Kuntz ID, Perry KM. (1993) Structure-based 
discovery of inhibitors of thymidylate synthase. Science, 259(5100):1445–1450.  
23. Miller MD, Kearsley SK, Underwood DJ, Sheridan RP. (1994) FLOG: a system to 
select „quasi-flexible‟ ligands complementary to a receptor of known three-
dimensional structure. J Comput Aided Mol Des., 8(2):153–174.  
24. Diller DJ, Merz KM Jr. (2001) High throughput docking for library design and library 
prioritization. Proteins, 43(2):113–124. 
25. Burkhard P, Taylor P, Walkinshaw MD. (1998) An example of a protein ligand found 
by database mining: description of the docking method and its verification by a 2.3 A 
X-ray structure of a thrombin-ligand complex. J Mol Biol., 277(2):449–466. 
26. Matthias Rarey, Bernd Kramer and Thomas Lengauer. (1997)  Multiple automatic 
base selection: Protein–ligand docking based on incremental construction without 
manual intervention. Journal of Computer-Aided Molecular Design, 11:369–384. 
   70              ISSN: 2278-8115 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
27. Matthias Rarey, Bernd Kramer, Thomas Lengauer and Gerhard Klebe. (1996) A Fast 
Flexible Docking Method using an Incremental Construction Algorithm.J. Mol. Biol., 
261, 470–489. 
28. Ewing TJ, Makino S, Skillman AG, Kuntz ID. (2001) DOCK 4.0: search strategies for 
automated molecular docking of flexible molecule databases. J Comput Aided Mol 
Des., 15(5):411– 428. 
29. Rarey M, Kramer B, Lengauer T, Klebe G. (1996) A fast flexible docking method 
using an incremental construction algorithm. J Mol Biol., 261(3):470–489.  
30. Kramer, B.; Rarey, M. and Lengauer, T. (1999) Evaluation of the FLEXX incremental 
construction algorithm for protein–ligand docking. Proteins, 37(2):228-241. 
31. Miller MD, Kearsley SK, Underwood DJ and Sheridan RP. (1994) FLOG: a system to 
select 'quasi-flexible' ligands complementary to a receptor of known three-
dimensional structure. J. Comput. Aided Mol. Des., 8: 153-174. 
32. Jain, A.N. (2003) Surflex: fully automatic flexible molecular docking using a 
molecular similarity-based search engine. J. Med. Chem., 46(4): 499-511. 
33. Jain, A.N. (2007) Surflex-Dock 2.1: robust performance from ligand energetic 
modeling, ring flexibility, and knowledge-based search. J. Comput. Aided Mol. Des., 
21(5):281-306. 
34. Welch W, Ruppert J, Jain AN. (1996) Hammerhead: fast, fully automated docking of 
flexible ligands to protein binding sites. Chem Biol., 3(6):449–462. 
35. Schnecke V, Kuhn LA. (2000) Virtual Screening with Solvation and Ligand-Induced 
Complementarity. Perspectives in Drug Discovery and Design, 20:171–190. 
36. Zsoldos Z, Reid D, Simon A, Sadjad BS and Johnson AP. (2006) eHiTS: an 
innovative approach to the docking and scoring function problems. Curr Protein Pept 
Sci., 7(5):421–435. 
37. Miranker A, Karplus M. (1991) Functionality maps of binding sites: a multiple copy 
simultaneous search method. Proteins, 11(1):29–34. 
38. Eisen MB, Wiley DC, Karplus M, Hubbard RE. (1994) HOOK: a program for finding 
novel molecular architectures that satisfy the chemical and steric requirements of a 
macromolecule binding site. Proteins, 19(3):199–221. 
39. Christian R. Schubert, Collin M. Stultz. (2009). The multi-copy simultaneous search  
methodology: a fundamental tool for structure-based drug design. Journal of 
Computer-Aided Molecular Design. 23: 475-489.  
   71              ISSN: 2278-8115 
 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
 
40. Taylor RD, Jewsbury PJ and Essex JW. (2002) A review of protein-small molecule 
docking methods. Journal of Computer-Aided Molecular Design, 16: 151–166. 
41. Bohm HJ. (1992) The computer program LUDI: a new method for the denovo design 
of enzyme inhibitors. J Comput. Aid. Mol. Des., 6:61–78. 
42. Bohm HJ. (1992) LUDI: rule-based automatic design of new substituents for enzyme 
inhibitor leads. J Comput Aided Mol Des., 6(6):593–606.  
43. Tami J. Marrone, James M. Briggs, and J. Andrew McCammon. (1997) 
STRUCTURE-BASED DRUG DESIGN: Computational Advances. Annu. Rev. 
Pharmacol. Toxicol., 37:71–90. 
44. Goodsell DS, Lauble H, Stout CD and Olson AJ. (1993) Automated docking in 
crystallography: analysis of the substrates of aconitase. Proteins, 17(1):1–10.  
45. Hart TN and Read RJ. (1992) A multiple-start Monte Carlo docking method. Proteins, 
13(3):206–222. 
46. Goodsell DS and Olson AJ. (1990) Automated docking of substrates to proteins by 
simulated annealing. Proteins, 8(3):195–202. 
47. Abagyan R, Totrov M and Kuznetsov D. (1994) ICM-A new method for protein 
modeling and design:Applications to docking and structure prediction from the 
distorted native conformation. J. Comput. Chem., 15:488–506. 
48. McMartin C and Bohacek RS. (1997) QXP: powerful, rapid computer algorithms for 
structure-based drug design. J Comput Aided Mol Des., 11(4):333–344. 
49. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK and Olson AJ. 
(1998) Automated docking using a Lamarckian genetic algorithm and an empirical 
binding free energy function. Journal of Computational Chemistry, 19(14):1639–
1662. 
50. Jones G, Willett P, Glen RC, Leach AR and Taylor R. (1997) Development and 
validation of a genetic algorithm for flexible docking. J Mol Biol., 267(3):727–748. 
51. Oshiro CM, Kuntz ID and Dixon JS. (1995) Flexible ligand docking using a genetic 
algorithm. J Comput Aided Mol Des., 9(2):113–130. 
52. Garrett M. Morris, David S. Goodsell. (1998) Automated Docking Using a 
Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function , 
Journal of Computational Chemistry, 19(14):1639-1662. 
   72              ISSN: 2278-8115 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
53. Rafael ¨Ord¨og and Vince Grolmusz. (2008) Evaluating Genetic Algorithms in 
Protein-Ligand Docking. Bioinformatics Research and Applications, 4983:402-413. 
54. Raquel Dias1 and Walter Filgueira and de Azevedo Jr. (2008) Molecular Docking 
Algorithms., Current Drug Targets, 9(12):1040-1047. 
55. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW and Taylor RD. (2003) Improved 
protein-ligand docking using GOLD. Proteins, 52(4):609–623. 
56. Clark KP. Ajay. (1995) Flexible ligand docking without parameter adjustment across 
four ligandreceptor complexes. J Comput Chem., 16:1210–1226. 
57. Taylor JS and Burnett RM. (2000) DARWIN: a program for docking flexible 
molecules. Proteins, 41(2):173–191. 
58. Martin Karplus and J Andrew McCammon. (2002) Molecular dynamics simulations 
of biomolecules. Nature structural biology, 9:646-652. 
59. Bernard R. Brooks, Robert E. Bruccoleri, Barry D. Olafson, David J. States, S. 
Swaminathan and Martin Karplus. (1983) CHARMM: a program for macromolecular 
energy, minimization, and dynamics calculations. J. Comput Chem., 4(2):187-217. 
60. Weiner, P.W. and Kollman, P.A. (1981) AMBER: assisted model building with 
energy refinement. A general program for modelling molecules and their interactions. 
J. Comput Chem., 2:287-303. 
61. Walter R. P. Scott , Philippe H. Hünenberger , Ilario G. Tironi , Alan E. 
Mark , Salomon R. Billeter , Jens Fennen , Andrew E. Torda , Thomas Huber , Peter 
Krüger and Wilfred F. van Gunsteren (1999) The GROMOS biomolecular simulation 
program package. J. Phys. Chem. A 103(19):3596-3607. 
62. Kollman PA. (1993) Free energy calculations: Applications to chemical and 
biochemical phenomena. Chem. Rev., 93:2395–2417. 
63. Aqvist J, Luzhkov VB and Brandsdal BO. (2002) Ligand binding affinities from MD 
simulations. Acc. Chem Res., 35(6):358–365. 
64. Carlson HA and Jorgensen WL. (1995) An extended linear response method for 
determining free energies of hydration. J Phys Chem., 99:10667–10673. 
65. Bohm HJ. (1998) Prediction of binding constants of protein ligands: a fast method for 
the prioritization of hits obtained from de novo design or 3D database search 
programs. J Comput Aided Mol Des., 12(4):309–323. 
66. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ and Freer 
ST. (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: 
   73              ISSN: 2278-8115 
 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
 
conformationally flexible docking by evolutionary programming. Chem Biol., 
2(5):317–324. 
67. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Arthurs S, Colson AB, Freer 
ST, Larson V, Luty BA, Marrone T and Rose PW. (2000) Deciphering common 
failures in molecular docking of ligand protein complexes. J Comput Aided Mol Des., 
14(8):731–751. 
68. Jain AN. (1996) Scoring noncovalent protein-ligand interactions: a continuous 
differentiable function tuned to compute binding affinities. J Comput Aided Mol Des., 
10(5):427–440. 
69. Head RD, Smythe ML, Oprea TI, Waller CL, Green SM and Marshall GR. (1996) 
VALIDATE: A New Method for the Receptor-Based Prediction of Binding Affinities 
of Novel Ligands. J. Am. Chem.Soc., 118:3959–3969. 
70. Gehlhaar DK, Moerder KE, Zichi D, Sherman CJ, Ogden RC and Freer ST. (1995) 
De novo design of enzyme inhibitors by Monte Carlo ligand generation. J Med 
Chem., 38(3):466–472. 
71. Eldridge MD, Murray CW, Auton TR, Paolini GV and Mee RP. (1997) Empirical 
scoring functions: I. The development of a fast empirical scoring function to estimate 
the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des., 
11(5):425–445.  
72. Muegge I and Martin YC. (1999) A general and fast scoring function for protein-
ligand interactions: a simplified potential approach. J Med Chem., 42(5):791–804.  
73. Mitchell JBO, Laskowski RA, Alex A and Thornton JM. (1999) Bleep-potential of 
mean force describing protein-ligand interactions: I. generating potential. J. Comput. 
Chem., 20(11):1165–1176. 
74. Ishchenko AV and Shakhnovich EI. (2002) Small Molecule Growth 2001 
(SMoG2001): an improved knowledge-based scoring function for protein-ligand 
interactions. J Med Chem., 45(13):2770–2780. 
75. Feher M, Deretey E and Roy S. (2003) BHB: a simple knowledge-based scoring 
function to improve the efficiency of database screening. J Chem Inf Comput Sci., 
43(4):1316–1327. 
76. Verkhivker G, Appelt K, Freer ST and Villafranca JE. (1995) Empirical free energy 
calculations of ligandprotein crystallographic complexes. I. Knowledge-based ligand-
   74              ISSN: 2278-8115 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
protein interaction potentials applied to the prediction of human immunodeficiency 
virus 1 protease binding affinity. Protein Eng., 8(7):677–691. 
77. Wallqvist A, Jernigan RL and Covell DG. (1995) A preference-based free-energy 
parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease 
inhibitor design. Protein Sci., 4(9):1881–1903. 
78. Gohlke H, Hendlich M and Klebe G. (2000) Knowledge-based scoring function to 
predict protein-ligand interactions. J Mol Biol., 295(2):337–356. 
79. DeWitte RS and Shakhnovich EI. (1996) SMoG: de Novo Design Method Based on 
Simple, Fast, and Accurate Free Energy Estimates. 1 Methodology and Supporting 
Evidence. J. Am. Chem. Soc., 118(47):11733–11744. 
80. Charifson PS, Corkery JJ, Murcko MA and Walters WP. (1999) Consensus scoring: A 
method for obtaining improved hit rates from docking databases of three-dimensional 
structures into proteins. J Med Chem., 42(25):5100–5109. 
81. Sheng Y.  Huang  and Xiaoqin Zou. (2010). Advances and Challenges in Protein-
Ligand Docking. Int. J. Mol. Sci. 11: 3016-3034. 
82. Jiang F and Kim SH. (1991) Soft docking: Matching of molecular surface cubes. J. 
Mol. Biol., 219:79-102. 
83. Ferrari AM, Wei BQ, Costantino L and Shoichet BK. (2004) Soft docking and 
multiple receptor conformations in virtual screening. J. Med. Chem., 47:5076-5084. 
84. Desmet J, Wilson IA, Joniau M, De Maeyer M and Lasters I. (1997) Computation of 
the binding of fully flexible peptides to proteins with flexible side-chains. FASEB 
J.,11:164-172.  
85. Meiler J and Baker D. (2006) ROSETTALIGAND: Protein-small molecule docking 
with full side-chain flexibility. Proteins, 65:538-584. 
86. Apostolakis J, Pluckthun A and Caflisch A. (1998) Docking small ligands in flexible 
binding sites. J. Comput. Chem., 19:21-37. 
87. Knegtel RM, Kuntz ID and Oshiro CM. (1997) Molecular docking to ensembles of 
protein structures. J Mol Biol., 266(2):424–440. 
88. Changsheng Zhang and Luhua Lai. (2011). Towards structure-based protein drug 
design. Biochemical Society Transactions, 39: 1382-1387. 
89. Moreira IS, Fernandes PA and Ramos MJ. (2007) Hot spots: a review of the protein–
protein interface determinant amino-acid residues. Proteins, 68:803–812. 
   75              ISSN: 2278-8115 
 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
 
90. Liang S, Liu Z, Li W, Ni L and Lai L. (2000) Construction of protein binding sites in 
scaffold structures. Biopolymers, 54:515–523. 
91. Chia-Hsien Lee, Hsuan-Cheng Huang, and Hsueh-Fen Juan. (2011). Reviewing 
Ligand-Based Rational Drug Design: The Search for an ATP Synthase Inhibitor. Int. 
J. Mol. Sci.  12; 5304-5318. 
92. Chayan Acharya, Andrew Coop, James E. Polli, and Alexander D. MacKerell Jr. 
(2011). Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the 
Conformationally Sampled Pharmacophore Approach. Curr Comput Aided Drug Des.  
7(1): 10–22. 
93. Ehrlich P. (1909) Ueber den jetzigen Stand der Chemotherapie. Ber. Dtsch. Chem. 
Ges., 42:17–47.  
94. Van Drie JH. (2003) Pharmacophore discovery-lessons learned. Curr. Pharm. Des., 
9:1649–1664. 
95. Yang SY. (2010) Pharmacophore modeling and applications in drug discovery: 
challenges and recent advances. Drug Discov., 15:444–450. 
96. Esposito EX, Hopfinger AJ and Madura JD. (2004) Methods for applying the 
quantitative structureactivity relationship paradigm. Methods. Mol. Biol., 275:131–
214. 
97. Perkins R, Fang H, Tong W and Welsh WJ. (2003) Quantitative structure-activity 
relationship methods: perspectives on drug discovery and toxicology. Environ. 
Toxicol. Chem., 22:1666–1679. 
98. Fujita T and Hansch C. (1964) p-σ-π Analysis. A Method for the Correlation of 
Biological Activity and Chemical Structure. J. Am. Chem. Soc., 86(6):1616–1626. 
99. Topliss JG. (1993) Some Observations on Classical QSAR. Perspectives in Drug 
Discovery and Design, 1:253–268. 
100. Arkadiusz Z. Dudek, Tomasz Arodz and Jorge Gálvez. (2006). Computational 
Methods in Developing Quantitative Structure-Activity Relationships (QSAR): A 
Review. Combinatorial Chemistry & High Throughput Screening. 9: 213-228. 
101. Cramer RD, Patterson DE and Bunce JD. (1988) Comparative Molecular-Field 
Analysis (Comfa) .1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. 
Am. Chem. Soc., 110(18):5959–5967. 
   76              ISSN: 2278-8115 
IJCB Vol. 5, No. 1, August 2016, 54 – 76      http://www.ijcb.in 
102. Klebe G, Abraham U and Mietzner, T. (1994) Molecular similarity indices in a 
comparative analysis (CoMSIA) of drug molecules to correlate and predict their 
biological activity. J. Med. Chem., 37:4130–4146. 
103.  Smellie A, Teig SL and Towbin P. (1995) Poling: Promoting Conformational 
Variation. J. Comput. Chem., 16:171–187. 
104.  David C.Rees, Miles Congreve, Christopher W.Murray and Robin Carr (2004). 
Fragment-       Based Lead Discovery: Nature vol 3:660-672. 
105. Tim Mitchell and Mike Cherry. Fragment-Based Drug Designing: Innovation in      
Pharmaceutical Technology :34-36. 
106. Dr Jianling Wang, Dr Laszlo Urban (2004) The impact of early ADME profiling on 
drug discovery and development strategy. Drug Discovery World Fall   73-86. 
107. Han van de Waterbeemd and Eric Gifford (2003)  Admet in silico modelling: 
       towards prediction paradise?. Nature Publishing Group. 2:192-204. 
108.  Ania de la Nuez, Rolando Rodríguez (2008) Current methodology for the 
assessment  of ADME-Tox properties on drug candidate molecules. Biotecnología 
Aplicada . 25:97-110. 
 
 
 
 
  
 
 
